CU20190005A7 - Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico - Google Patents

Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico

Info

Publication number
CU20190005A7
CU20190005A7 CU2019000005A CU20190005A CU20190005A7 CU 20190005 A7 CU20190005 A7 CU 20190005A7 CU 2019000005 A CU2019000005 A CU 2019000005A CU 20190005 A CU20190005 A CU 20190005A CU 20190005 A7 CU20190005 A7 CU 20190005A7
Authority
CU
Cuba
Prior art keywords
chewing gum
orally administrable
pharmaceutical agent
aqueous formulations
formulations including
Prior art date
Application number
CU2019000005A
Other languages
English (en)
Inventor
Allen [Ca/Ca] Greenspoon
Original Assignee
Allen [Ca/Ca] Greenspoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen [Ca/Ca] Greenspoon filed Critical Allen [Ca/Ca] Greenspoon
Publication of CU20190005A7 publication Critical patent/CU20190005A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se proporciona una formulación de goma de mascar o formulación de base acuosa administrable por vía oral, que comprende una o más partículas que contienen agentes farmacéuticos que proporcionan una liberación rápida de los agentes farmacéuticos para su absorción en el sistema circulatorio de un mamífero. Las presentes formulaciones proporcionan un medio alternativo aceptable para administrar agentes farmacéuticos como los derivados de cannabinoides para el tratamiento del dolor y otras dolencias.</p> <p> </p> <p> </p>
CU2019000005A 2016-07-28 2017-07-28 Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico CU20190005A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/222,019 US9833408B1 (en) 2016-07-28 2016-07-28 Orally administrable formulation
PCT/CA2017/050904 WO2018018152A1 (en) 2016-07-28 2017-07-28 Novel orally administrable formulation

Publications (1)

Publication Number Publication Date
CU20190005A7 true CU20190005A7 (es) 2020-03-04

Family

ID=60451833

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000005A CU20190005A7 (es) 2016-07-28 2017-07-28 Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico

Country Status (13)

Country Link
US (2) US9833408B1 (es)
EP (2) EP4353221A3 (es)
JP (2) JP7050777B2 (es)
AU (2) AU2017301239B2 (es)
BR (2) BR122020007418B1 (es)
CL (1) CL2019000209A1 (es)
CO (1) CO2019001895A2 (es)
CU (1) CU20190005A7 (es)
IL (1) IL264484A (es)
MX (1) MX383529B (es)
PE (1) PE20190738A1 (es)
WO (1) WO2018018152A1 (es)
ZA (2) ZA201901116B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11699166B2 (en) 2017-10-09 2023-07-11 American Express Travel Related Services Company, Inc. Multi-merchant loyalty point partnership
US11397962B2 (en) 2017-10-09 2022-07-26 American Express Travel Related Services Company, Inc. Loyalty point distributions using a decentralized loyalty ID
US11449887B2 (en) 2017-10-09 2022-09-20 American Express Travel Related Services Company, Inc. Systems and methods for loyalty point distribution
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US11951086B2 (en) * 2018-04-03 2024-04-09 Pure Green Pharmaceuticals, Inc. Tablet or composition having n-acyl ethanolamine and cannabinoid
EP3549579A1 (en) * 2018-04-03 2019-10-09 Sanofi Winthrop Industrie Oral gum formulation and fabrication process thereof
US11728995B2 (en) 2018-04-09 2023-08-15 American Express Travel Related Services Company, Inc. Reward point transfers using blockchain
US10783545B2 (en) 2018-04-19 2020-09-22 American Express Travel Related Services Company, Inc. Reward point redemption for cryptocurrency
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020151789A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11013685B2 (en) * 2019-01-25 2021-05-25 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
WO2020151793A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Chewing gum with improved delivery of cannabinoids
US11191720B2 (en) 2019-01-25 2021-12-07 Nordiccan A/S Chewing gum with improved delivery of cannabinoids
US11406593B2 (en) 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
MX2021008935A (es) * 2019-01-25 2021-08-24 Nordiccan As Goma de mascar de cannabinoide con alcoholes de azucar.
EP3914226A1 (en) * 2019-01-25 2021-12-01 NordicCan A/S Cannabinoid chewing gum with improved release of cannabinoids
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
CN113365503A (zh) * 2019-01-25 2021-09-07 诺狄更斯公司 具有高强度甜味剂的大麻素口香糖
US11154496B2 (en) * 2019-01-25 2021-10-26 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US10933017B2 (en) 2019-03-01 2021-03-02 Nordiccan A/S Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11253473B2 (en) * 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
US10799450B2 (en) 2019-03-01 2020-10-13 Medcan Pharma A/S Tableted cannabinoid chewing gum with layered structure
US11471405B2 (en) 2019-03-01 2022-10-18 Nordiccan A/S Tableted chewing gum with enhanced delivery of cannabinoids
US11331309B2 (en) * 2019-06-05 2022-05-17 Cure Pharmaceutical Holding Corp. Methods and compositions for improving sleep
US20220273558A1 (en) * 2019-08-02 2022-09-01 Advanced Female Technologies Llc Chewing Gum Compositions Containing Cannabinoids
US20220378677A1 (en) * 2019-10-31 2022-12-01 M. Mustix Ltd Treatment of tooth decay using a chewing gum composition comprising cannabinoids
WO2021116825A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11058142B1 (en) 2020-10-01 2021-07-13 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same
US11363834B2 (en) 2020-10-01 2022-06-21 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing, product, and method of making the same
EP4243602A4 (en) * 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
WO2023064318A1 (en) * 2021-10-11 2023-04-20 Natural Extraction Systems, LLC Biphasic compositions comprising one or both of carbonate and phosphate
WO2025043046A1 (en) * 2023-08-22 2025-02-27 GlycosBio, INC. Latex-compatible oil-based compositions
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816265A (en) * 1986-12-23 1989-03-28 Warner-Lambert Company Sweetener delivery systems containing polyvinyl acetate
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US6132762A (en) * 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
ATE353629T1 (de) * 2000-03-09 2007-03-15 Gw Pharma Ltd Cannabis enthaltende pharmazeutische zusammensetzungen
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2184983A1 (en) * 2007-08-06 2010-05-19 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
WO2009120080A1 (en) * 2008-03-26 2009-10-01 Mareda Holding Bv Chewing gum compositions comprising cannabinoids
JP2012500843A (ja) * 2008-08-29 2012-01-12 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド マイクロパーティクル
JP5614571B2 (ja) * 2009-12-25 2014-10-29 ダイヤ製薬株式会社 咀嚼用ガム医薬品および咀嚼用ガム医薬品の製造方法
JP2014506894A (ja) * 2011-02-28 2014-03-20 テクノロジーズ・クロロス・インク 口腔吸収用の咀嚼可能なビヒクル
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US10071053B2 (en) * 2014-01-31 2018-09-11 Pocket Tea, Llc Tea composition for oral administration
US20160199299A1 (en) 2015-01-09 2016-07-14 Mark B. Uren Cannabis Infused Chewing Composition
CN105124747B (zh) * 2015-07-21 2018-04-10 中国烟草总公司广东省公司 一种烟草提取物微粒和胶基型口香烟及其制备方法
US11529329B2 (en) * 2016-05-27 2022-12-20 Nordiccan A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
CA2937471C (en) * 2016-07-28 2019-02-05 Allen Greenspoon Orally administrable formulation

Also Published As

Publication number Publication date
ZA202001037B (en) 2020-07-29
AU2017301239A1 (en) 2019-03-14
JP2019525963A (ja) 2019-09-12
MX383529B (es) 2025-03-14
US20180064645A1 (en) 2018-03-08
BR112019001572B1 (pt) 2021-11-03
EP4353221A2 (en) 2024-04-17
US9833408B1 (en) 2017-12-05
AU2017301239B2 (en) 2020-10-08
PE20190738A1 (es) 2019-05-23
IL264484A (en) 2019-02-28
US10456357B2 (en) 2019-10-29
JP7050777B2 (ja) 2022-04-08
EP3490539A1 (en) 2019-06-05
EP3490539B1 (en) 2024-03-13
BR122020007418B1 (pt) 2021-11-03
AU2020257071A1 (en) 2020-11-19
CL2019000209A1 (es) 2019-09-27
EP4353221A3 (en) 2024-07-10
JP2022088537A (ja) 2022-06-14
WO2018018152A1 (en) 2018-02-01
CO2019001895A2 (es) 2019-05-31
ZA201901116B (en) 2020-10-28
MX2019001169A (es) 2019-08-29
BR112019001572A2 (pt) 2019-05-07
EP3490539A4 (en) 2020-08-12
AU2020257071B2 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
NZ726746A (en) Stable cannabinoid formulations
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
CL2019001462A1 (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla.
CO2017000354A2 (es) Desmopresina estabilizada
AR104504A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CL2025001949A1 (es) Formulaciones líquidas orales de netupitant y palonosetrón
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
ECSP19044926A (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
AR106029A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue